

Cutting-Edge Developments in 1,3,4-Oxadiazole Derivatives: Synthesis, Properties, and Applications

Gajanan M. Amle¹, Rajendra K. Wanare²

¹Department of Chemistry, Govt. Vidarbha Institute of Humanities and sciences, Amravati, Maharashtra, India

²Department of Chemistry, Arvindbabu Deshmukh College, Bharsingi, Maharashtra, India

ARTICLE INFO

Article History:

Accepted : 01 Jan 2025

Published : 10 Jan 2025

Publication Issue :

Volume 12, Issue 7

January-February-2025

Page Number :

196-199


ABSTRACT

Recent advancements in 1,3,4-oxadiazole derivatives have positioned them as versatile compounds with broad applications in medicinal chemistry and materials science. These heterocyclic compounds, containing nitrogen and oxygen, exhibit significant antibacterial, anticancer, and anti-diabetic activities. This review highlights innovative synthetic methods that improve yield, efficiency, and sustainability. It also discusses the diverse applications of these derivatives, including drug design, corrosion inhibition, and optoelectronic devices. The growing interest in 1,3,4-oxadiazole derivatives underscores their potential to drive innovation in various scientific and industrial sectors.

Keywords: 1,3,4-Oxadiazole, Synthesis, Properties, Anticancer, Optoelectronics.

I. INTRODUCTION

1,3,4-Oxadiazole derivatives are versatile compounds with applications in medicinal chemistry, materials science, and environmental protection. Their unique structure, containing nitrogen and oxygen, imparts valuable properties, making them effective in drug design, with activities like antimicrobial, anticancer, and anti-diabetic effects. Additionally, their electronic properties enable use in optoelectronic devices such as LEDs and organic solar cells. These derivatives are also explored as corrosion inhibitors. This review focuses on recent advancement in their synthetic properties, applications, emphasizing novel methods and the growing potential for innovation in various fields.



Graphical overview

1,3,4-Oxadiazole and its derivatives represent an important class of heterocyclic compounds with significant synthetic and pharmacological applications. Their versatility stems from their unique structural properties and diverse biological activities, making them attractive for drug discovery and development. The discovery and exploration of 1,3,4-oxadiazoles have revealed their potential as anticancer agents. Detchokul et al. [1] and Torre et al. [2] highlighted their role in targeting cancer pathways, emphasizing their cytotoxicity against various cancer cell lines. Similarly, Puthiyapurayil et al. [3] synthesized oxadiazole derivatives that demonstrated promising anticancer activity and underscoring their therapeutic activities. Song et al. [4] further corroborated these findings by developing oxadiazole-based molecules with significant potency against cancer cells. In addition to their anticancer properties, oxadiazoles exhibit antimicrobial activity. De Oliveira et al. [5] and Liu et al. [6] reported the synthesis of derivatives with potent antibacterial and antifungal properties, addressing the growing issue of antimicrobial resistance. Kumar et al. [7] expanded this scope by synthesizing oxadiazole compounds with broad-spectrum antimicrobial efficacy, suggesting their potential in combating multidrug-resistant pathogens.

Another significant application of 1,3,4-oxadiazoles lies in their anti-inflammatory properties. Bostrom et al. [8] discussed the structural modifications of oxadiazole derivatives to enhance their anti-inflammatory effects. Zhang et al. [9] and Macaev et al. [10] further demonstrated their utility in alleviating inflammation through inhibition of key enzymes involved in inflammatory pathways. These studies underscore the therapeutic versatility of oxadiazole in managing inflammatory diseases. The role of oxadiazoles in treating neurological disorders has also been extensively studied. Jha et al. [11] and Sangshetti et al. [12] synthesized derivatives that showed neuro-protective effects and potentially aiding in the treatment of disorders like Alzheimer's and epilepsy. Rajak et al. [13] added to this by designing oxadiazole-based compounds with enhanced central nervous system activity and further validating their application in neurology. In cardiovascular research, oxadiazole derivatives have emerged as potent agents. Ramaprasad et al. [14] and Ziedan et al. [15] developed molecules targeting cardiovascular conditions, including hypertension and thrombosis. These derivatives were shown to modulate key pathways and providing therapeutic benefits in cardiovascular health.

The potential of 1,3,4-oxadiazoles as antiviral agents has gained considerable attention. Kashaw et al. [16] synthesized oxadiazole compounds effective against various viral infections and addressing the need for novel antiviral therapies. Gollapalli et al. [17] and Guang et al. [18] further validated these findings, demonstrating their efficacy against viral replication mechanisms.

From a synthetic chemistry perspective, oxadiazole derivatives offer considerable advantages in terms of structural diversity and reactivity. Babic et al. [19] and Dannhardt et al. [20] emphasized the methodologies for synthesizing oxadiazoles and highlighting their applicability in medicinal chemistry. Manjunatha et al. [21] demonstrated innovative approaches to oxadiazole synthesis, showcasing their adaptability in creating novel therapeutic agents. Bozic et al. [22] and Polkam et al. [23] explored their applications in developing advanced materials with unique physical and chemical properties. These studies open new avenues for oxadiazoles beyond traditional medicinal uses. Overall, the literature on 1,3,4-oxadiazoles underscores their immense potential across various scientific disciplines. Their biological activities, coupled with synthetic versatility, position them as a cornerstone in heterocyclic chemistry and drug discovery. Future research should focus on optimizing their pharmacokinetic properties and expanding their applications in emerging therapeutic areas.

II. REFERENCES

- [1]. S. Detchokul, E. D. Williams, M. W. Parker, A. G. Frauman, Br. J. Pharmacol. 2014, 171, 5462.
- [2]. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, CA Cancer J. Clin. 2015, 65, 87.
- [3]. P. Puthiyapurayil, B. Poojary, C. Chikkanna, S. K. Buridipad, Eur. J. Med. Chem. 2012, 53, 203.
- [4]. M. X. Song, C. J. Zheng, X. Q. Deng, L. P. Sun, Y. Wu, L. Hong, Y. J. Li, Y. Liu, Z. Y. Wei, M. J. Jin, H. R. Piao, Eur. J. Med. Chem. 2013, 60, 376.
- [5]. C. S. De Oliveira, B. F. Lira, J. M. Barbosa-Filho, J. G. F. Lorenzo, P. F. De Athayde-Filho, Molecules 2012, 17, 10192.
- [6]. Z. Liu, J. Zhao, X. Huang, Bioorg. Med. Chem. Lett. 2006, 16, 1828.
- [7]. K. A. Kumar, P. Jayaroopa, G. V. Kumar, Int. J. ChemTech Res. 2012, 4, 1782.
- [8]. J. Bostrom, A. Hogner, A. Llinas, E. Wellner, A. T. Plowright, J. Med. Chem. 2012, 55, 1817.
- [9]. F. Zhang, X. L. Wang, J. Shi, S. F. Wang, Y. Yin, Y. S. Yang, W. M. Zhang, H. L. Zhu, Bioorg. Med. Chem. 2014, 22, 468.
- [10]. F. Macaev, Z. Ribkovskaia, S. Pogrebnoi, V. Boldescu, G. Rusu, N. Shvets, A. Dimoglo, A. Geronikaki, R. Reynolds, Bioorg. Med. Chem. 2011, 19, 6792.
- [11]. K. K. Jha, A. Samad, Y. Kumar, M. Shaharyar, R. L. Khosa, J. Jain, V. Kumar, P. Singh, Eur. J. Med. Chem. 2010, 45, 4963.
- [12]. J. N. Sangshetti, A. R. Chabukswar, D. B. Shinde, Bioorg. Med. Chem. Lett. 2011, 21, 444.
- [13]. H. Rajak, T. B. Singh, A. Singh, K. Raghuvanshi, A. K. Sah, R. Veerasamy, P. C. Sharma, P. R. Singh, M. D. Kharya, Bioorg. Med. Chem. Lett. 2013, 23, 864.
- [14]. G. C. Ramaprasad, B. Kalluraya, B. S. Kumar, R. K. Hunnur, Eur. J. Med. Chem. 2010, 45, 4587.
- [15]. N. I. Ziedan, F. Stefanelli, S. Fogli, A. D. Westwell, Eur. J. Med. Chem. 2010, 45, 4523.
- [16]. S. K. Kashaw, V. Gupta, V. Kashaw, P. Mishra, J. P. Stables, N. K. Jain, Med. Chem. Res. 2010, 19, 250.
- [17]. N. R. Gollapalli, N. S. S. Kavuri, P. Kumba, S. Yangalasetty, R. R. Nadendla, Asian J. Pharm. Anal. Med. Chem. 2015, 3, 20.
- [18]. S. H. Guang, T. Loon-Seng, Z. Qingdong, N. P. Paras, Chem. Rev. 2008, 108, 1245.

- [19]. M. M. Babic, K. M. Antic, J. S. J. Vukovic, B. D. Bozic, S. B. B. Davidovic, J. M. Filipovic, S. Tomic, J. Mater. Sci. 2015, 50, 906.
- [20]. G. Dannhardt, W. Kiefer, Eur. J. Med. Chem. 2001, 36, 109.
- [21]. K. Manjunatha, B. Poojary, P. L. Lobo, J. Fernandes, N. S. Kumari, Eur. J. Med. Chem. 2010, 45, 5225.
- [22]. B. D. Bozic, J. R. Rogan, D. D. Poleti, N. P. Trisovic, B. D. Bozic, G. S. Uscumlic, Chem. Pharm. Bull. 2012, 60, 865.
- [23]. (a) N. Polkam, P. Rayam, J. S. Anireddy, S. Yennam, H. S. Anantaraju, S. Dharmarajan, Y. Perumal, S. S. Kotapalli, R. Ummanni, S. Balasubramanian, Bioorg. Med. Chem. Lett. 2015, 25, 1398. (b) N. Polkam, V. R. Ramaswamy, P. Rayam, T. R. Allaka, H. S. Anantaraju, S. Dharmarajan, Y. Perumal, D. Gandamalla, N. R. Yellu, S. Balasubramanian, Bioorg. Med. Chem. Lett. 2016, 26, 2562. (c) N. Kuntala, J. Telu, V. Banothu, S. B. Nallapati, J. S. Anireddy, S. Pal, Med. Chem. Commun. 2015, 6, 1612. (d) T. R. Allaka, N. Polkam, P. Rayam, J. Sridhara, N. S. Garikapati, R. U. Kotapalli, J. S. Anireddy, Med. Chem. Res. 2016, 25, 977. (e) J. Mareddy, S. B. Nallapati, J. Anireddy, Y. P. Devi, L. P. Mangamoori, R. Kapavarapu, S. Pal, Bioorg. Med. Chem. Lett. 2013, 23, 6721.